leadf
logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics plans to unify the intellectual property ownership of its drugs and platform

The initiative would unlock value for potential partners and investors while simplifying IP protection for pipeline expansion efforts now underway

Antibe Therapeutics Inc - Antibe Therapeutics Inc plans to unify the intellectual property (IP) ownership of its drugs and platform
The company has commenced preliminary discussions to amalgamate with Antibe Holdings Inc

Antibe Therapeutics Inc (TSX:ATE) (OTCQB:ATBPF) (FRA:4B7), a clinical-stage company leveraging its hydrogen sulfide platform to develop safer medicines for pain and inflammation, wants to unify the intellectual property (IP) ownership of its drugs and platform.  

In a statement Friday, the company said it has commenced preliminary discussions to amalgamate with Antibe Holdings Inc. 

The company said it believes that such an initiative would unlock value for potential partners and investors, while simplifying IP protection for pipeline expansion efforts now underway.

READ: Antibe Therapeutics strengthens governance and US capital markets expertise with appointments of two independent directors

“As described in our ongoing disclosures, the company was founded with an exclusive license from [Antibe] Holdings,” said Antibe Therapeutics CEO Dan Legault. “Based on this IP, we have achieved human proof-of-concept for otenaproxesul and developed compelling preclinical data for our other pipeline drugs.”

Legault added: "As we map out strategic initiatives with prospective partners and healthcare-specialized investors, we expect full ownership of the underlying IP to strengthen our corporate position. It also represents another step in our growth strategy, complementing our recent graduation to the TSX, share consolidation and the appointment of U.S.-based directors.”

Toronto-based Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation, safer non-steroidal anti-inflammatory drugs (NSAIDs) for pain and inflammation arising from a wide range of medical conditions

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

 

 

Quick facts: Antibe Therapeutics Inc

Price: 4.85 CAD

TSX:ATE
Market: TSX
Market Cap: $220.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 08/12/2020

2 min read